After a strong finish to its fiscal year, driven by strength in international markets and continued global adoption of its flagship product, MiniMed Group Inc. (MMED) is optimistic about its long-term growth prospects.
MiniMed Group, a subsidiary of Medtronic plc (MDT), began trading on the Nasdaq Global Select Market on March 6, 2026, pricing its IPO at $20 per share.
For the full fiscal year ended April 24, 2026, the company's worldwide net sales were $3.102 billion, up 14.2% on a reported basis and 8.0% organically. Its flagship product is the MiniMed 780G system, a self-adjusting basal insulin pump system with new autocorrection dosing, which is both FDA-cleared and CE-marked.
For comments and feedback contact: editorial@rttnews.com
May 22, 2026 14:46 ET Minutes of the latest Fed policy session was the highlight of the week along with survey data on the U.S. housing market. In Europe, survey data signaled the trends in the euro area private sector. Further, consumer price inflation data from the U.K. was in focus. In Asia, various economic indicators from China drew attention to the health of the economy.